Table 1.
Patient characteristics comparing cases and controls
| Cases (n=47) | Controls (n=94) | P-value | |
|---|---|---|---|
| Agea (median with range) | 54 (range 21–73, 25–75% range 34–61) | 54 (range 20–74, 25–75% range 46–61) | 0.19 |
| Male gender | 57.5% (27) | 61.7% (58) | 0.63 |
| Race/ethnicity | |||
| Caucasian | 83.0% (39) | 88.3% (83) | 0.46 |
| African-American | 6.4% (3) | 6.4% (6) | |
| Other | 10.6% (5) | 5.3% (5) | |
| Type of transplant | |||
| Allogeneic—related | 21.2% (10) | 19.2% (18) | 0.99 |
| Allogeneic—unrelated | 27.7% (13) | 29.8% (28) | |
| Allogeneic—umbilical cord | 6.4% (3) | 6.4% (6) | |
| Autologous | 44.7% (21) | 44.7% (42) | |
| Underlying malignancy | |||
| NHL | 36.2% (17) | 36.2% (34) | |
| AML | 25.5% (12) | 25.5% (24) | |
| MM/amyloid | 23.4% (11) | 23.4% (22) | |
| ALL | 4.3% (2) | 4.3% (4) | |
| CLL | 4.3% (2) | 4.3% (4) | |
| CML | 2.1% (1) | 2.1% (2) | |
| HD | 2.1% (1) | 2.1% (2) | |
| MDS | 2.1% (1) | 2.1% (2) | |
| Medical comorbidities | |||
| DM | 10.6% (5) | 12.8% (12) | 0.72 |
| HTN | 31.9% (15) | 37.2% (35) | 0.53 |
| COPD/asthma | 17.0% (8) | 8.5% (8) | 0.13 |
| CAD | 2.1% (1) | 7.5% (7) | 0.20 |
| CHF | 12.8% (6) | 3.2% (3) | 0.03 |
| CKD/ESRD | 6.4% (3) | 5.3% (5) | 0.80 |
| Prior HSCT | 6.4% (3) | 6.4% (6) | 1.0 |
| Hypothyroidism | 8.5% (4) | 6.4% (6) | 0.64 |
| OSA | 10.6% (5) | 5.3% (5) | 0.25 |
| DVT/PE | 17.0% (8) | 10.6% (10) | 0.28 |
| Conditioning regimen | |||
| Ablative | 54.4% (25) | 51.6% (48) | 0.76 |
| Non-myeloablative | 45.6% (21) | 48.4% (45) | |
| Immunosuppresive therapy | |||
| Tacrolimus | 27.7% (13) | 28.7% (27) | 0.90 |
| Corticosteroids | 25.5% (12) | 16% (15) | 0.17 |
| Mycophenolate | 12.8% (6) | 4.3% (4) | 0.06 |
| Sirolimus | 2.1% (1) | 2.1% (2) | 1.0 |
| Cyclosporine | 0% (0) | 1.1% (1) | 0.48 |
| Anti-infective prophylaxis | |||
| Pneumocystis | 27.7% (13) | 33.0% (31) | 0.52 |
| Fungi | 50.0% (23) | 41.5% (39) | 0.34 |
| Herpesvirus | 70.2% (33) | 73.4% (69) | 0.60 |
| Bacteria | 8.5% (4) | 5.3% (5) | 0.47 |
| Laboratory values | |||
| WBC (mean±s.d.) | 6.5±7.7 | 5.1±3.5 | 0.16 |
| ANC (mean±s.d.) | 4.1±4.1 | 3.3±2.5 | 0.17 |
| Cr (mean±s.d.) | 1.1±0.7 | 1.0±0.5 | 0.14 |
| ALT (mean±s.d.) | 45.3±9.7 | 44.7±7.9 | 0.96 |
Abbreviations: ALT=alanine aminotransferase; CAD=coronary artery disease; CHF=congestive heart failure; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; Cr=creatinine; DM=diabetes mellitus; DVT=deep venous thrombosis; ESRD=end-stage renal disease; HD=hodgkin disease; HSCT=hematopoietic SCT; HTN=hypertension; MDS=myelodysplasia; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; OSA=obstructive sleep apnea; PE=pulmonary embolism.
aMedian values were felt to be a better measure of central tendency for age and so the Wilcoxon rank-sum test was used to generate a P-value. Other continuous variables in the table were analyzed using two sample t-tests.